Summary of Pharvaris (PHVS) Conference Call Company Overview - Pharvaris is focused on bradykinin-mediated angioedema, particularly hereditary angioedema (HAE) [3][4] - The company is pioneering science for patient choice in therapy options [3] - Pharvaris has two late-stage programs in Phase III for its molecule, Cryptevant, which serves both as prophylaxis and on-demand treatment [3][4] Market Insights - The global market for HAE is projected to grow to approximately $5.2 billion by 2036 [4] - There remains a significant unmet need in the HAE market, with no sustainable first-mover advantage for new entrants [4][5] - HAE is a genetic condition that significantly impacts the quality of life, with unpredictable attacks of swelling [5][6] Clinical Data and Pipeline - The prevalence of HAE is estimated to be between 1 in 10,000 to 1 in 80,000 individuals globally [7] - Patients typically experience around 12 to 24 attacks per year, influencing their treatment choices [8] - Cryptevant is a B2 receptor antagonist and the first and only small molecule orally available for this indication [9][10] - The company has two Phase III studies ongoing: RAPID E3 for on-demand treatment and Chapter III for prophylaxis, with top-line data expected in Q1 2026 and the second half of 2026, respectively [13][14] Efficacy and Safety - In Phase II studies, Cryptevant showed an 84.5% reduction in attacks at a 40 mg/day dosage compared to placebo [16][17] - The open-label extension study indicated a further 93% attack reduction compared to baseline [17] - The Phase III study for prophylaxis is designed to compare confirmed attacks against a placebo, with a focus on safety and efficacy [18][22] Future Plans and Regulatory Status - Pharvaris is planning a pivotal trial for acquired angioedema, with orphan drug status granted in Europe and the U.S. for both on-demand and prophylactic treatments [15] - The company aims to become a leader in the bradykinin-mediated angioedema space and is committed to engaging with the HAE community [23][24] Key Takeaways - Pharvaris is well-funded and has a strong R&D team with extensive experience in the therapeutic area [5] - The company is positioned to potentially become the standard of care in oral therapies for HAE, pending successful clinical trials and regulatory approvals [23][24]